Megalac

Hydrotalcite, the active ingredient in Megalac, is an antacid presented as an oral dosage form for oral use. It neutralizes excess gastric acid and is indicated for relief of heartburn, acid indigestion, gastric ulcer and gastro‑oesophageal reflux disease in adults and adolescents.

GNH USA supplies Megalac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Megalac is an antacid that acts on excess gastric acidity to relieve symptoms of several upper‑digestive conditions.

- Heartburn: provides rapid relief of burning sensation by neutralising excess stomach acid. - Acid indigestion: reduces discomfort and bloating associated with hyperacidity. - Gastric ulcer: promotes ulcer healing by decreasing acid exposure to the mucosa. - Gastro‑oesophageal reflux disease: alleviates reflux symptoms through acid neutralisation.

Megalac may cause unwanted reactions, most of which are mild and transient.

Common Side Effects: - Mild constipation or loose stools. - Temporary metallic taste in the mouth. - Mild abdominal discomfort or bloating. - Nausea. - Dry mouth.

Serious or Rare Side Effects: - Hypermagnesemia in patients with severe renal impairment. - Severe allergic reactions such as rash, itching, swelling or difficulty breathing. - Electrolyte imbalance leading to muscle weakness or irregular heartbeat.

Before using Megalac, consider the following safety measures.

- Pregnancy: consult a healthcare professional before use. - Renal impairment: use with caution and under medical supervision. - Concomitant medications: review all current drugs for potential interactions. - Elderly patients: dosage may need adjustment due to altered metabolism. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Megalac can affect the absorption or action of several medicines.

Major Interactions (Avoid): - Tetracycline antibiotics: reduced absorption and effectiveness. - Iron supplements: decreased antacid efficacy and iron uptake. - Fluoroquinolone antibiotics: impaired absorption.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of anticoagulant effect. - Digoxin: monitor serum levels for potential changes. - Beta‑blockers: may require dose adjustment.